Objective: To evaluate the incremental cost-utility ratio (ICUR) of idelalisib in combination with rituximab (IR) versus rituximab monotherapy (R) in the treatment of patients with relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL), from the Spanish National Health System (NHS) perspective. Results: Compared to R, 2L IR treatment resulted in QALY gain of 3.147 (4.965 versus 1.818). Total costs were €118 254 for IR versus €23 874 for R. ICUR was €29 990/QALY gained with IR versus R. In the PSA, IR was cost-effective in 78% of iterations using a threshold of €45 000/QALY.
usually alternate between response and relapse periods, with the responses becoming less frequent and durable over time, and relapses becoming more frequent, especially after a second relapse. 2 Until recently, the treatment options for relapsed or refractory CLL were limited and included either retreatment with a prior regimen (fludarabine or chlorambucil combinations with rituximab) or agents such as ofatumumab, bendamustine, rituximab alone or combinations. 3 Idelalisib (Zydelig ® ) is a small oral molecule, that is a potent and selective inhibitor of phosphatidylinositol 3-kinase p110δ (PI3Kδ), which is expressed in B-cell malignancies and is central to multiple signalling pathways that drive proliferation, survival, homing and retention of malignant cells in lymphoid tissues and bone marrow. By inhibiting PI3K delta kinases, idelalisib induces apoptosis and inhibits proliferation in primary patient-derived tumour samples and in cell lines derived from malignant B cells. 4 Idelalisib is indicated in combination with an anti-CD20 monoclonal antibody (rituximab or ofatumumab)
for the treatment of adult patients with CLL who have received at least one prior therapy, or as first-line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies. 5, 6 The regimen has demonstrated an acceptable benefit-risk ratio being an optimal treatment in older patients or for patients with several comorbidities, which frequently make them non-eligible for standard chemoimmunotherapy. 3 New oral targeted therapies have shown relevant efficacy improvements over the treatments frequently used for CLL; however, their current pricing is expected to have a substantial impact on the cumulative cost of CLL patients care. 7, 8 The objective of this study was to evaluate the cost-utility of treatment with idelalisib in combination with rituximab versus rituximab as monotherapy in adults with CLL previously treated (who have received at least one prior therapy), from the perspective of the Spanish National Health System (NHS). Rituximab monotherapy was the selected comparator for this analysis, in alignment with the idelalisib pivotal trial. In that trial, due to the inclusion criteria of grade ≥3 neutropenia or thrombocytopenia due to prior myelotoxicity, or estimated creatinine clearance <60 mL/min or CIRS score >6, the patients were unable to receive cytotoxic therapy, therefore the control arm received rituximab monotherapy. 5 
| MATERIAL AND METHODS

| Model structure
A partitioned survival model of area under the curve (AUC) designed with three mutually exclusive health states based on survival status (alive/dead), and the status of those who are alive by disease progression (preprogression, postprogression) was developed ( Figure 1 To accurately capture the treatment costs, and to best quantify the average number of cycles of therapy received, a cycle length of one week was used, with costs and benefits accrued over a lifetime horizon (30 years, given the mean age at diagnosis).
The model design and structure, disease stages, population, adverse event (AE) management, disease management and resource consumption were validated by three experts in the haemato-oncology field, to ensure that this analysis is representative of the Spanish setting.
F I G U R E 1 Overall model schematic. PFS, progression-free survival; OS, overall survival Annual discount rates of 3.0% for both costs and health effects were applied to be aligned with the latest published Spanish recommendations. 9 
| Population
The cohort of CLL patients had specific anthropometric characteristics, with a mean body surface area of 1.80 m 2 which is representative of the Spanish population. 10 The mean age of patients at diagnosis was set at 70 years, being 58.8% male patients.
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| Clinical data
In the comparison performed, data were obtained directly from the pivotal clinical trial comparing the efficacy and safety of the combination of idelalisib and rituximab versus rituximab alone. and its proportion that was assumed to be equivalent to that seen with bendamustina monotherapy. 12 Serious infections have been observed with idelalisib in experimental studies involving patient groups for whom it is not licensed, or in unlicensed combinations with other medicines. 13 As this analysis is based on 116 trial (pivotal trial for current indication), this new safety issue was not included. Table 1 presents the frequency of each AE in IR arm and in R arm.
| Mortality
Five-and 10-year relative survival estimates were 80.2-82.4 and 59.5%-64.7%, respectively. 14 For this reason, competitive mortality from non-CLL causes would have a very secondary effect on the target population, so no correction was made to adjust all-cause mortality by age and gender.
| Resource use and disease management
The analysis was performed from a Spanish NHS perspective; therefore, only direct medical costs (drugs, administration, monitoring and AE and disease management) were included.
The simulation starts with all patients receiving treatment with idelalisib in combination with rituximab or with rituximab monotherapy. Table 1 shows posologies and duration for the different treatment options considered in the model.
| Treatment administration
In the present model, administration of intravenous immunotherapy requires qualified professionals. Therefore, it is assumed for each administration, a day visit to a hospital haematology clinic is required. For the administration of oral medication, self-administration by the patient is assumed, without additional consumption of healthcare resources.
| Treatment monitoring
Prior to the administration of the therapy, certain laboratory tests or premedication administration is generally needed to ensure the patient is fit to receive treatment. The expert panel considered that the consumption of healthcare resources prior to drug administration should be equivalent for both treatment options (conservative approach) ( Table 1) .
| Disease management
In addition to the medical visits required for the administration and monitoring of medication, and management of therapy-related toxicity, the model assumed that CLL management also entails nonmedication-related medical visits and hospital admissions, which have been included in the model as aggregated costs (Table 1) . 
| Utilities and disutilities
To estimate the quality-adjusted life years (QALY), different utility values were considered depending on the health status of patients. The term "utility" refers to the quality perceived by patients based on their health status and receives a value between 1 (perfect health) and 0 (state of health equivalent to death).
Quality of life data were obtained from a population in England and Scotland, using the standard gamble method. 15 Utilities applied for patients in the preprogression state were 0.91, in cases of complete response to treatment, 0.84 for partial response to treatment, 0.78 for patients without changes (perfect health in newly diagnosed patients) and 0.71 for patients on treatment. For patients in the postprogression disease state, the assigned utility was 0.68.
The present analysis, in addition to the utilities in function of the patients' health status, applies a decrease in utility (disutility) to the appearance of any AE. In the absence of specific disutility values in CLL patients, it was considered that the disutility values by the appearance of an AE are not determined by the underlying pathology and are independent of the type of cancer or the treatment received. The disutilities due to AE used in the analysis were obtained from scientific literature. Despite the wide range of articles used to obtain the information, some assumptions had to be made based on expert opinion (Table 1) .
| Costs
According to the perspective of the study, only direct healthcare costs were included. All costs were obtained from Spanish sources and are reported in euros for the year 2016. 
T A B L E 1 Model inputs
T A B L E 1 (Continued)
The cost of intravenous administration was also taken from a
Spanish database. Table 1 shows the unitary costs of the different health resources considered for both the management of the disease and AE. All unitary costs and managing costs of AE (grade 3/4) ( Table 1) were obtained from a database of national health costs. 20 Costs were expressed in euros for the year 2016.
| Sensitivity analysis
Deterministic and probabilistic sensitivity analyses (PSA) were performed to test the robustness of the model and to determine the impact of uncertainty on the incremental cost-utility ratio (ICUR). For the deterministic sensitivity analyses, the following parameters were varied: time horizon (5 and 10 years horizon), discount rate (0% and 5%), drug cost (−25% and −45%), parametric curve for overall survival (OS) extrapolation (exponential distribution), progression-free survival (PFS) curve using log-logistic distribution (it was the second bestfitting model) and not considering disutility values.
Probabilistic analyses by Monte Carlo simulation were performed.
The value of each key model parameter would vary within a specific probability distribution assigned to each parameter. This process was repeated 1000 times to provide a distribution of the model results.
| RESULTS
The results are presented as cost differences, life-years gained (LYG) and QALY gained per patient treated with idelalisib plus rituximab (Table 2 ).
According to the deterministic sensitivity analysis (Figure 2 ), the parameters having most influence on the results were the time horizon (shorter time horizon, higher ICUR) and the distribution that adjusts the PFS data (considering a PFS based on log-logistic distribution, the second best-fitting model, higher ICUR).
As an average of the 1000 iterations performed on the probabilistic sensitivity analysis, an ICUR of €34 436 per additional QALY was obtained. Figure 3 shows the cost-effectiveness plane of idelalisib in combination with rituximab when compared to rituximab alone. Almost all of the results are found in the first quadrant; most simulations of the combination of idelalisib plus rituximab were more effective and associated with higher cost than treatment with rituximab monotherapy. The remaining simulations were associated with lower effectiveness and higher costs, so they were considered as dominated. It was also found that the likelihood of idelalisib plus rituximab being a cost-effective strategy compared with rituximab monotherapy was 78%, given a frequently referenced threshold of €45 000 per QALY gained in Spain 21 ( Figure 4 ).
| DISCUSSION
The present study is the first cost-utility analysis of idelalisib in compared to rituximab monotherapy remains below €45 000 per QALY, a threshold frequently used as reference value in economic evaluations performed in Spain. 21 Considering this willingness-topay threshold, the combination of idelalisib and rituximab is costeffective in 78% of simulations. Conversely, our study has some limitations. First, the parameters used in the modelling have been extracted from different sources.
However, all of the variables are based on official sources or in publications with a high level of clinical evidence and have been validated by three expert haemato-oncologists. The potentially associated uncertainty in some of the parameters was tested by a probabilistic sensitivity analysis.
Second, due to a lack of utility data availability in the Spanish population, utilities are taken from a study that evaluated this information in patients with CLL in the UK, 15 such as has been done in other CLL Spanish economic evaluations. 10 In this sense, there is published evidence suggesting that utility values for different health states in six European countries (Finland, Germany, the Netherlands, Spain, Sweden and the UK) could be described by a common model; therefore, no relevant influence is expected to be associated with the use of utilities from UK population, instead of specific values for Spanish patients. 27 The model includes disutilities in order to capture the impact of the drug safety profile on patient's quality of life. In line with the approach commonly used in late-stage oncology models, it was assumed that all treatment-related AEs occur in the first model cycle. Despite the potential interest for modelling late onset events in the idelalisib plus rituximab arm, particularly pneumonitis and diarrhoea, the required information on these events was not reported in the pivotal trial. 5 Moreover, the absolute rate over the randomised follow-up period included in the clinical study report was low, so to avoid unnecessary complexity, it was decided to exclude these events from the model.
The sensitivity analysis results did not reveal any important variations in the estimated incremental ratio.
Within the present model, the progression health state is intended to reflect third and later lines of therapy. Due to the existing uncertainty related to the costs of additional lines of therapy, no one-off cost was applied to patients entering the progressed state.
Finally, the drug acquisition costs were calculated assuming that treatment duration is equivalent to the median PFS. This assumption is frequently employed in economic evaluations for oncohaematology drugs, but it is a conservative approach, as treatment duration is usually shorter than median PFS. It is likely, therefore, that a lower ICUR would result if mean treatment duration was applied.
Despite the limitations described above, the results of the sensitivity analysis confirm that the uncertainty associated with the parameters used in the modelling did not represent a significant deviation from the results obtained in the base case. In summary, our analysis shows that idelalisib in combination with rituximab increases the survival of CLL adult patients previously treated (who have received at least one prior therapy), compared to rituximab monotherapy, and can therefore be a cost-effective approach from the perspective of the Spanish NHS.
